DNA binding properties and cytotoxic effects of two double rollover cycloplatinated (II) complexes on cancer cell lines.

In this study, the DNA binding capacity and cytotoxic effects of two double rollovers cycloplatinated complexes, [Pt2(µ-bpy-2H)(CF3COO)2(PPh3)2] and [Pt2(µ-bpy-2H)(I)2(PPh3)2] denoted as C1 and C2, respectively, were evaluated. By using UV-Visible spectroscopy the intrinsic binding constant (Kb) of C1 and C2 to DNA were determined as 2.9 × 105 M-1, and 5.4 × 105 M-1, respectively. Both the compounds were able to quench the fluorescence of ethidium bromide as a well known DNA intercalator. The calculated Stern-Volmer quenching constants (Ksv) for C1 and C2 were 3.5 × 103 M-1, and 1.2 × 104 M-1, respectively. Upon interaction of both the compounds with DNA, increase in viscosity of DNA solution were observed, further confiming the involvement of intercalative interactions between the complexes and DNA. The cytotoxic effects of complexes in compare to cisplatin were evaluated on different cancer cell lines by MTT assay. Interestingly, C2 showed the highest cytotoxicity on A2780R, a cisplatin resistant-cell line. Induction of apoptosis by the complexes was proved by flowcytometry. In all the studied cell lines, the extent of apoptosis induced by C2 was comparable or higher than cisplatin. Cisplatin induced more necrosis in all the cancer cell lines in the tested concentration.

Bilateral metalloheterocyclic systems based on palladacycle and piperidine-2,4-dione pharmacophores.

The design of molecules with effective anticancer properties constructed from both dually active metal complex and organic fragments is a novel trend in medicinal chemistry. This concept suggests the impact of a drug on several biological targets or the synergistic action of both fragments as a single unit. We propose that the combination of a Pd-metallocomplex fragment and an organic unit can be an interesting model for anticancer drug discovery. The first phase in the development of such suggested molecules is the synthesis of bilateral metallosystems containing bioactive 6-substituted piperidin-2-one and a palladated N-phenylpyrazolic fragment. Both fragments were incorporated into one molecule through the fused pyrazole-piperidine-2-one unit followed by pyrazol-directed cyclopalladation of the phenyl-group with Pd(OAc)2. An effect of acceleration of the rate of the palladation by NH-lactam was observed. The synthesized hybrid palladacycles have been characterized and tested for their cytotoxic activity on three cancerous cell lines as PPh3 complexes, revealing structures with potential for further development and structural optimization.

Pt@Metal-Organic Framework (ZIF-8) Thin Films Obtained at a Liquid/Liquid Interface as Anode Electrocatalysts for Methanol Fuel Cells: Different Approaches in the Synthesis.

Smart membranes, nanodevices, chemical sensors, and catalytic coatings are some of the applications that make the metal-organic framework (MOF) thin films very important. Encapsulation of nanoparticles in the porous structure of MOFs can lead to the formation of effective catalysts with new unique properties and wide range of applications that may not be obtained by MOFs individually. Three main strategies, ship-in-a-bottle, bottle-around-the-ship, and in situ synthesis including the simultaneous formation of the two components, were applied for the synthesis of Pt(0)@zeolitic imidazolate framework-8 (ZIF-8) thin films at the toluene/water interface. The effects of platinum precursor transfer directions toward the interface on the properties of the films were investigated by using the [PtCl2(cod)] (where cod = cis,cis-1,5-cyclooctadiene) complex soluble in toluene as the upper phase and K2PtCl4 soluble in water as the lower phase. The six obtained films with different morphologies were applied as electrocatalysts for the methanol oxidation reaction. Considerable current density, mass activity, catalyst stability, activation energy, exchange current density, maximum power, and long-term poisoning rate are some of the advantages of the Pt(0)@ZIF-8 catalysts synthesized using the in situ strategy and K2PtCl4 as the platinum precursor. Furthermore, we report the formation of Pt@ZIF-8 nanorods at the interfaces without using any stabilizer or template. Our results suggest that the in situ strategy at the liquid/liquid interface is one of the best procedures for the synthesis of Pt(0)@ZIF-8 thin films as a suitable anode electrocatalyst for methanol fuel cells.

Half-Sandwich Cyclometalated RhIII Complexes Bearing Thiolate Ligands: Biomolecular Interactions and In Vitro and In Vivo Evaluations.

A class of cyclometalated RhIII complexes [Cp*Rh(ppy)(SR)] bearing thiolate ligands, Cp* = pentamethylcyclopentadienyl, ppy = 2-phenylpyridinate, and R = pyridyl (Spy, 2), pyrimidyl (SpyN, 3), benzimidazolyl (Sbi, 4), and benzothiazolyl (Sbt, 5), were produced and identified by means of spectroscopic methods. The in vitro cytotoxicity of the RhIII compounds in three different human mortal cancerous cell lines (ovarian, SKOV3; breast, MCF-7; lung, A549) and a normal lung (MRC-5) cell line were evaluated, indicating the selectivity of these cyclometalated RhIII complexes to cancer cells. Complex 5, selected for in vivo experiment, has shown an effective inhibition of tumor growth in SKOV3 xenograft mouse model relative to control (p-values < 0.05 and < 0.01). Importantly, the outcomes of H&E (hematoxylin and eosin) staining and hematological analysis revealed negligible toxicity of 5 compared to cisplatin on a functioning of the main organs of mouse. Molecular docking, UV-vis, and emission spectroscopies (fluorescence, 3D fluorescence, synchronous) techniques were carried out on 1-5 to peruse the mechanism of the anticancer activities of these complexes. The obtained data help to manifest the binding affinity between the rhodium compounds and calf thymus DNA (CT-DNA) through the interaction by DNA minor groove and moderate binding affinity with bovine serum albumin (BSA), particularly with the cavity in the subdomain IIA. It can be concluded that the Rh-thiolate complexes are highly promising leads for the development of novel effective DNA-targeted anticancer drugs.

Tetranuclear rollover cyclometalated organoplatinum-rhenium compounds; C-I oxidative addition and C-C reductive elimination using a rollover cycloplatinated dimer.

The novel tetranuclear Pt(IV)-Re(VII) complex [Pt2Me4(OReO3)2(PMePh2)2(µ-bpy-2H)], 4, is synthesized through the reaction of silver perrhenate with a new rollover cycloplatinated(IV) complex [Pt2Me4I2(PMePh2)2(µ-bpy-2H)], 3. In complex 4, while 2,2'-bipyridine (bpy) acts as a linker between two Pt metal centers, oxygen acts as a mono-bridging atom between Pt and Re centers through an unsupported Pt(IV)-O-Re(VII) bridge. The precursor rollover cycloplatinated(IV) complex 3 is prepared by the MeI oxidative addition reaction of the rollover cycloplatinated(II) complex [Pt2Me2(PMePh2)2(µ-bpy-2H)], 2. Complex 2 shows a metal-to-ligand charge-transfer band in the visible region, which was used to investigate the kinetics and mechanism of its double MeI oxidative addition reaction. Based on the experimental findings, the classical SN2 mechanism was suggested for both steps and supported by computational studies. All complexes are fully characterized using multinuclear NMR spectroscopy and elemental analysis. Attempts to grow crystals of the rollover cycloplatinated(IV) dimer 3 yielded a new dimer rollover cyclometalated complex [Pt2I2(PMePh2)2(µ-bpy-2H)], 5, presumably from the C-C reductive elimination of ethane. The identity of complex 5 was confirmed by single crystal X-ray diffraction analysis.

Ligand-Controlled Csp2-H versus Csp3-H Bond Formation in Cycloplatinated Complexes: A Joint Experimental and Theoretical Mechanistic Investigation.

The cyclometalated platinum(II) complexes [PtMe(C∧N)(L)] [1PS: C∧N = 2-phenylpyridinate (ppy), L = SMe2; 1BS: C∧N = benzo[h]quinolate (bhq), L = SMe2; 1PP: C∧N = ppy, L = PPh3; and 1BP: C∧N = bhq, L = PPh3] containing two different cyclometalated ligands and two different ancillary ligands have been investigated in the reaction with CX3CO2H (X = F or H). When L = SMe2, the Pt-Me bond rather than the Pt-C bond of the cycloplatinated complex is cleaved to give the complexes [Pt(C∧N)(CX3CO2)(SMe2)]. When L = PPh3, the selectivity of the reaction is reversed. In the reaction of [PtMe(C∧N)(PPh3)] with CF3CO2H, the Pt-C∧N bond is cleaved rather than the Pt-Me bond. The latter reaction gave [PtMe(κ1N-Hppy)(PPh3)(CF3CO2)] as an equilibrium mixture of two isomers. For L = PPh3, no reaction was observed with CH3CO2H. The reasons for this difference in selectivity for complexes 1 are computationally discussed based on the energy barrier needed for the protonolysis of the Pt-Csp3 bond versus the Pt-Csp2 bond. Two pathways including the direct one-step acid attack at the Pt-C bond (SE2) and stepwise oxidative-addition on the Pt(II) center followed by reductive elimination [SE(ox)] are proposed. A detailed density functional theory (DFT) study of these protonations along with experimental UV-vis kinetics suggests that a one-step electrophilic attack (SE2) at the Pt-C bond is the most likely mechanism for complexes 1, and changing the nature of the ancillary ligand can influence the selectivity in the Pt-C bond cleavage. The effect of the nature of the acid and cyclometalated ligand (C∧N) is also discussed.

Ligand-Mediated C-Br Oxidative Addition to Cycloplatinated(II) Complexes and Benzyl-Me C-C Bond Reductive Elimination from a Cycloplatinated(IV) Complex.

Reaction of the Pt(II) complexes [PtMe2(pbt)], 1a, (pbt = 2-(2-pyridyl)benzothiazole) and [PtMe(C^N)(PPh2Me)] [C^N = deprotonated 2-phenylpyridine (ppy), 1b, or deprotonated benzo[h]quinoline (bhq), 1c] with benzyl bromide, PhCH2Br, is studied. The reaction of 1a with PhCH2Br gave the Pt(IV) product complex [PtBr(CH2Ph)Me2(pbt)]. The major trans isomer is formed in a trans oxidative addition (2a), while the minor cis products (2a' and 2a″) resulted from an isomerization process. A solution of Pt(II) complex 1a in the presence of benzyl bromide in toluene at 70 °C after 7 days gradually gave the dibromo Pt(IV) complex [Pt(Br)2Me2(pbt)], 4a, as determined by NMR spectroscopy and single-crystal XRD. The reaction of complexes 1b and 1c with PhCH2Br gave the Pt(IV) complexes [PtMeBr(CH2Ph)(C^N)(PPh2Me)] (C^N = ppy; 2b; C^N = bhq, 2c), in which the phosphine and benzyl ligands are trans. Multinuclear NMR spectroscopy ruled out other isomers. Attempts to grow crystals of the cycloplatinated(IV) complex 2b yielded a previously reported Pt(II) complex [PtBr(ppy)(PPh2Me)], 3b, presumably from reductive elimination of ethylbenzene. UV-vis spectroscopy was used to study the kinetics of reaction of Pt(II) complexes 1a-1c with benzyl bromide. The data are consistent with a second-order SN2 mechanism and the first order in both the Pt complex and PhCH2Br. The rate of reaction decreases along the series 1a ≫ 1c > 1b. Density functional theory calculations were carried out to support experimental findings and understand the formation of isomers.

PtSn Nanoalloy Thin Films as Anode Catalysts in Methanol Fuel Cells.

Reactions of SnX2 (X = Cl, Br) with [PtMe2(bipy)], 1, (bipy = 2,2'-bipyridine), followed by NaBH4 reduction at the toluene/water interface in the presence or absence of graphene oxide support rendered PtSn nanoalloy thin films. They were characterized by powder X-ray diffraction, X-ray photoelectron spectroscopy, and transmission electron microscopy. The electrocatalytical activity of the PtSn thin films was investigated in the methanol oxidation reaction. Our studies showed that the PtSn/reduced-graphene oxide (RGO) thin film gave better catalytic results for MOR in comparison to bare PtSn or Pt thin films. A maximum jf/jb ratio (jf and jb are the maximum current densities in the forward and backward scans, respectively) of 6.77 was obtained for the PtSn/RGO thin film deriving from the 1 + SnBr2 + NaBH4 sequence.

Discovery and mechanistic investigation of Pt-catalyzed oxidative homocoupling of benzene with PhI(OAc)2.

We present a Pt-catalyzed direct coupling of benzene to biphenyl. This catalytic reaction employs a cyclometalated platinum(ii) complex [PtMe(bhq)(SMe2)] (bhq = benzo[h]quinolate) with PhI(OAc)2 as an oxidant and does not require an acid, a co-catalyst or a solvent. The reaction kinetics and characterization of potential catalytic species are reported. The reaction is first-order in Pt and second-order in benzene, which implicates the second C-H activation step as rate-determining. A Pt(ii)/Pt(iv) catalytic cycle is suggested. The reaction commences by oxidation of the Pt(ii) complex to give the platinum(iv) species [Pt(bhq)(SMe2)(OAc)2](OAc) followed by C-H activation of benzene to afford the intermediate [PtPh(bhq)(SMe2)(OAc)](OAc) concurrently with the release of HOAc. A second benzene molecule reacts similarly to give the diphenyl intermediate [PtPh2(bhq)(SMe2)](OAc). C-C bond forming reductive elimination ensues to regenerate Pt(ii) and complete the catalytic cycle. The proposed mechanism has been examined by DFT computations, which provide support to experimental findings.

Cycloplatinated(II) Derivatives of Mercaptopurine Capable of Binding Interactions with HSA/DNA.

In this study, two new bis-cyclometalated Pt(II) complexes, [Pt(C^N)(S^N)] [S^N = deprotonated 6-mercaptopurine (6-MP) and C^N = deprotonated 2-phenylpyridine (ppy), 2a; C^N = deprotonated benzo[h]quinoline (bhq), 2b], are synthesized by the reaction of [PtR(SMe2)(C^N)] (R = Me or p-MeC6H4) with 1 equiv of 6-mercaptopurine (6-HMP) at room temperature. The complexes are fully characterized using 1H and 13C NMR spectroscopies, electrospray ionization mass spectrometry, and elemental analysis. Biomolecular interaction of complex 2a with human serum albumin (HSA) is studied by fluorescence, UV-vis, and circular dichroism (CD) spectroscopies. The binding constants (Kb) and number of binding sites (n) are evaluated using the Stern-Volmer equation. The intrinsic fluorescence of protein is quenched by a static quenching mechanism, with a binding constant of Kb ∼ 105 reflecting a high affinity of complex 2a for HSA. The thermodynamic parameters (ΔH°, ΔG°, and ΔS°) indicate that the interaction is a spontaneous process and hydrophobic forces play a main role in the reaction. The displacement experiments demonstrate that the reactive binding sites of HSA to complex 2a are mainly located within its hydrophobic cavity in subdomain IIA (site I). Synchronous fluorescence spectra reveal that complex 2a affected the microenvironment of tryptophan-214 residues in subdomain IIA of HSA. In the case of interaction of complex 2b and HSA, because of overlapping of the emission spectra of complex 2b with HSA, chemometric approaches are applied. The results indicate significant interaction between the tryptophan residue of HSA and complex 2b. Moreover, the binding of Pt(II) complexes 2a and 2b causes a reduction of the α-helix content of HSA, as obtained by far-UV CD spectroscopy. The average binding distance (r) between Pt(II) complexes and HSA is obtained by Förster's resonance energy-transfer theory. Also, a molecular docking simulation reveals that π-π-stacking and hydrophobic interactions between these complexes and HSA are significant. Furthermore, the interactions of platinum complexes, 2, with calf-thymus DNA (CT-DNA) are investigated. The UV-vis results and ethidium bromide competitive studies support an intercalative interaction of both Pt(II) complexes with DNA. The new complexes 2 are also screened for anticancer activities. The results show that complexes 2 exhibit significant anticancer activity against the K562 (chronic myelogenous leukemia) cell line.

Chelating and Bridging Roles of 2-(2-Pyridyl)benzimidazole and Bis(diphenylphosphino)acetylene in Stabilizing a Cyclic Tetranuclear Platinum(II) Complex.

The reaction of complex [Pt(Me)(DMSO)(pbz)], 1, (pbz = 2-(2-pyridyl)benzimidazolate) with [PtMe(Cl)(DMSO)2], B, followed by addition of bis(diphenylphosphino)acetylene (dppac), gave the novel tetranuclear platinum complex [Pt4Me4(µ-dppac)2(pbz)2Cl2], 2, bearing both the pbz and dppac ligands. In this structure, the pbz ligands are both chelating and bridging to stabilize the tetraplatinum framework. The tetranuclear Pt(II) complex was fully characterized by NMR spectroscopy, X-ray crystallography, and mass spectrometry, and its electronic structure was investigated and supported by DFT calculations.

A double rollover cycloplatinated(ii) skeleton: a versatile platform for tuning emission by chelating and non-chelating ancillary ligand systems.

Described here is the synthesis and characterization of heteroleptic binuclear platinum(ii) complexes of the type [Pt2(µ-bpy-2H)(S^S)2] and [Pt2(µ-bpy-2H)(L)2(X)2], containing a 2,2'-bipyridine-based double rollover cycloplatinated core (Pt(µ-bpy-2H)Pt), in combination with the anionic S^S- chelate ligands di(ethyl)dithiocarbamate (dedtc) and O,O'-di(cyclohexyl)dithiophosphate (dcdtp) or non-chelating L/X ancillary ligands (PPh3/Me, t-BuNC/Me, PPh3/SCN and PPh3/N3). The new complexes were characterized using multinuclear (1H, 31P and 195Pt) NMR spectroscopy and some of them additionally using single crystal X-ray diffraction. The absorption and photoluminescence of the complexes show a strong dependence on the ancillary ligands. Upon excitation at 365 nm, in a CH2Cl2 rigid matrix (77 K), the complexes exhibit structured emission bands with λmax between 488 nm and 525 nm and vibrational spacing around 1350 cm-1, indicating the excited states centered on the cyclometalated ligand (3ILCT) with some mixing 3MLCT characteristics. In the case of the PPh3/N3 complex, a dual emission band (orange color) is observed in the solid state at 298 K for which the low energy band arises from an aggregation-induced emission (AIE). Upon lowering the temperature (77 K), thermochromism is observed (orange to yellow) which is accompanied by the intensification of the high energy band (ligand-centered structured band). Finally, in order to rationalize the obtained photophysical data, complete DFT (density functional theory) and TD-DFT (time-dependent DFT) calculations were performed on the selected complexes.

Effects of the number of cyclometalated rings and ancillary ligands on the rate of MeI oxidative addition to platinum(ii)-pincer complexes.

Organoplatinum(ii)-pincer complexes [Pt(C^N^C)(L)] (2a; L = PPh2Me, 2b; L = pyridine (py), 2c; L = 4-picoline (pic)) are synthesized by the reaction of [Pt(C^N^C)(DMSO)], 1, with 1 equiv. of L, where HC^N^CH = 2,6-diphenylpyridine. Complexes 2 have 5d(Pt) →π*(pincer) metal-to-ligand charge-transfer bands in the visible region, which were used to easily follow the kinetics of their reactions with MeI by using UV-vis spectroscopy. An SN2 mechanism is suggested and the proposed intermediates were supported by DFT calculations. Consistent with the proposed mechanism, the rates of the reactions at different temperatures were slower for L = PPh2Me than those for L = N-donor ligands and large negative ΔS‡ values were found for all oxidative addition reactions. The rates are almost 2 times slower for L = PPh2Me as compared to L = 4-picoline because of the steric effects and the electronic effects transmitted through the ligands. To investigate the effect of the number of cyclometalated rings on the rate of MeI oxidative addition, the kinetics of the reaction of [Pt(Ph)(ppy)(py)] (Hppy = 2-phenylpyridine) and [Pt(Ph)2(py)2] (having 1 and zero cyclometalated ring, respectively) with MeI were also studied and a correlation between the number of cyclometalated rings and the rate of the oxidative addition reaction was found.

The influence of thiolate ligands on the luminescence properties of cycloplatinated(ii) complexes.

Complexes [Pt(C^N)(PPh3)Cl] (C^N = bzq (7,8-benzoquinolinyl, A) and ppy (2-phenylpyridinyl, B)) were reacted with various thiolate ligands to afford complexes [Pt(C^N)(PPh3)(κ1-S-SR)], C^N = bzq, R = SPh (thiophenolate, 1a); C^N = ppy, R = SPh (1b); C^N = bzq, R = Spy (pyridine-2-thiolate, 2a); C^N = ppy, R = Spy (2b); C^N = bzq, R = SpyN (pyrimidine-2-thiolate, 3a); C^N = ppy, R = SpyN (3b). Complexes 1-3 were characterized by NMR spectroscopy, and the solid-state structures of 1a and 2a were determined by X-ray diffraction methods. Replacing a chloride ligand with electron-rich thiolates changes the lowest energy singlet and triplet excited states to the ones that feature charge transfer from the thiolate (mixed with some metal character) to the C^N ligand, which was supported by TD-DFT calculations. All complexes are emissive at 298 K in the solid state except 2b and 3b, which are emissive only at 77 K having a less rigid structure compared to others. The emission of 1a and 1b originates from a low-energy excited state of dPt/πSR → π*C^N while 3a exhibits a 3LC/3MLCT transition. For 1a and 1b, the radiative rate and the quantum efficiency are higher in a rigid environment such as a solid compared to a polymer and solution. Decreasing the rigidity of the environment leads to a flexibility of rotation of the -SR around the axis of the Pt-S bond. So the geometry can be easily changed after radiation and the lowest lying triplet excited state would have the effective contribution of the dd* transition, which opens a nonradiative pathway at room temperature.

Which is the Stronger Nucleophile, Platinum or Nitrogen in Rollover Cycloplatinated(II) Complexes?

The rollover cyclometalated platinum(II) complexes [PtMe(2,X'-bpy-H)(PPh3)], (X = 2, 1a; X = 3, 1b; and X = 4, 1c) containing two potential nucleophilic centers have been investigated to elucidate which center is the stronger nucleophile toward methyl iodide. On the basis of DFT calculations, complexes 1b and 1c are predicted reacting with MeI through the free nitrogen donor to form N-methylated platinum(II) complexes, while complex 1a reacts through oxidative addition on platinum to give a platinum(IV) complex, which is in agreement with experimental findings. The reasons for this difference in selectivity for complexes 1a-1c are discussed based on the energy barrier needed for N-methylation versus oxidative addition reactions.

Phosphorescent heterobimetallic complexes involving platinum(iv) and rhenium(vii) centers connected by an unsupported µ-oxido bridge.

Heterobimetallic compounds [(C^N)LMe2Pt(µ-O)ReO3] (C^N = ppy, L = PPh3, 2a; C^N = ppy, L = PMePh2, 2b; C^N = bhq, L = PPh3, 2c; C^N = bhq, L = PMePh2, 2d) containing a discrete unsupported Pt(iv)-O-Re(vii) bridge have been synthesized through a targeted synthesis route. The compounds have been prepared by a single-pot synthesis in which the Pt(iv) precursor [PtMe2I(C^N)L] complexes are allowed to react easily with AgReO4 in which the iodide ligand of the starting Pt(iv) complex is replaced by an ReO4- anion. In these Pt-O-Re complexes, the Pt(iv) centers have an octahedral geometry, completed by a cyclometalated bidentate ligand (C^N), two methyl groups and a phosphine ligand, while the Re(vii) centers have a tetrahedral geometry. Elemental analysis, single crystal X-ray diffraction analysis and multinuclear NMR spectroscopy are used to establish their identities. The new complexes exhibit phosphorescence emission in the solid and solution states at 298 and 77 K, which is an uncommon property of platinum complexes with an oxidation state of +4. According to DFT calculations, we found that this emission behavior in the new complexes originates from ligand centered 3LC (C^N) character with a slight amount of metal to ligand charge transfer (3MLCT). The solid-state emission data of the corresponding cycloplatinated(iv) precursor complexes [PtMe2I(C^N)L], 1a-1d, pointed out that the replacement of I- by an ReO4- anion helps enhancing the emission efficiency besides shifting the emission wavelengths.

Mechanism of Me-Re Bond Addition to Platinum(II) and Dioxygen Activation by the Resulting Pt-Re Bimetallic Center.

Unusual cis-oxidative addition of methyltrioxorhenium (MTO) to [PtMe2(bpy)], (bpy = 2,2'-bipyridine) (1) is described. Addition of MTO to 1 first gives the Lewis acid-base adduct [(bpy)Me2Pt-Re(Me)(O)3] (2) and subsequently affords the oxidative addition product [(bpy)Me3PtReO3] (3). All complexes 1, MTO, 2, and 3 are in equilibrium in solution. The structure of 2 was confirmed by X-ray crystallography, and its dissociation constant in solution is 0.87 M. The structure of 3 was confirmed by extended X-ray absorption fine structure and X-ray absorption near-edge structure in tandem with one- and two-dimensional NMR spectroscopy augmented by deuterium and 13C isotope-labeling studies. Kinetics of formation of compound 3 revealed saturation kinetics dependence on [MTO] and first-order in [Pt], complying with prior equilibrium formation of 2 with oxidative addition of Me-Re being the rate-determining step. Exposure of 3 to molecular oxygen or air resulted in the insertion of an oxygen atom into the platinum-rhenium bond forming [(bpy)Me3PtOReO3] (4) as final product. Density functional theory analysis on oxygen insertion pathways leading to complex 4, merited on the basis of Russell oxidation pathway, revealed the involvement of rhenium peroxo species.

Comparative study on the interaction of two binuclear Pt (II) complexes with human serum albumin: Spectroscopic and docking simulation assessments.

Human serum albumin (HSA) principally tasks as a transport carrier for a vast variety of natural compounds and pharmaceutical drugs. In the present study, two structurally related binuclear Pt (II) complexes containing cis, cis-[Me2Pt (µ-NN) (µ-dppm) PtMe2] (1), and cis, cis-[Me2Pt(µ-NN)(µ dppm) Pt((CH2)4)] (2) in which NN=phthalazine and dppm=bis (diphenylphosphino) methane were used to investigate their interaction with HSA, using UV-Vis absorption spectroscopy, fluorescence, circular dichroism and molecular dynamic analyses. The spectroscopic results suggest that upon binding to HSA, the binuclear Pt (II) complexes could effectively induce structural alteration of this protein. These complexes can bind to HSA with the binding affinities of the following order: complex 2>complex 1. Moreover, the thermodynamic parameters of binding between these complexes and HSA suggested the existence of entropy-driven spontaneous interaction, which mostly dominated with the hydrophobic forces. The ANS fluorescence results also indicated that two binuclear Pt (II) complexes were competing for the binding to the hydrophobic regions on HSA. In addition, competitive displacement assay and docking simulation study revealed that complexes 1 and 2 bind to the drug binding sites II and I on HSA, respectively. Furthermore, complex 2, with the higher binding affinity for HSA, shows more denaturing effect on this protein. Considering the protein structural damages in the pathway of harmful side effects of platinum drugs, complex 1 with the moderate binding affinity and low denaturing effect might be of high significance.

Anticancer activity assessment of two novel binuclear platinum (II) complexes.

In the current study, two binuclear Pt (II) complexes, containing cis, cis-[Me2Pt (µ-NN) (µ-dppm) PtMe2] (1), and cis,cis-[Me2Pt(µ-NN)(µ dppm) Pt((CH2)4)] (2) in which NN=phthalazine and dppm=bis (diphenylphosphino) methane were evaluated for their anticancer activities and DNA/purine nucleotide binding properties. These Pt (II) complexes, with the non-classical structures, demonstrated a significant anticancer activity against Jurkat and MCF-7 cancer cell lines. The results of ethidium bromide/acridine orange staining and Caspase-III activity suggest that these complexes were capable to stimulate an apoptotic mechanism of cell death in the cancer cells. Using different biophysical techniques and docking simulation analysis, we indicated that these complexes were also capable to interact efficiently with DNA via a non-intercalative mechanism. According to our results, substitution of cyclopentane (in complex 2) with two methyl groups (in complex 1) results in significant improvement of the complex ability to interact with DNA and subsequently to induce the anticancer activity. Overall, these binuclear Pt (II) complexes are promising group of the non-classical potential anticancer agents which can be considered as molecular templates in designing of highly efficient platinum anticancer drugs.

Luminescence properties of some monomeric and dimeric cycloplatinated(ii) complexes containing biphosphine ligands.

The starting complexes [PtCl(C^N)(dmso)], in which C^N is either ppy = 2-phenylpyridinate, , or bhq = 7,8-benzo[h]quinolinate, , were prepared by a known method using the reaction of [PtCl2(dmso)2] with ppyH or bhqH, respectively, in toluene under reflux conditions. The reaction of [PtCl(C^N)(dmso)], or , with 1 equiv. of a number of biphosphine ligands, P^P, gave the cationic monomeric complexes [Pt(ppy)(P^P)]Cl, for which P^P is either 1,2-bis(diphenylphosphino)ethane (dppe), , 1,3-bis(diphenylphosphino)propane (dppp), , or bis(diphenylphosphino)methane (dppm), ; the bhq analogous complex [Pt(bhq)(dppe)]Cl, , was prepared similarly. However, the complex [Pt(ppy)(dfppe)]Cl, , in which dfppe is 1,2-bis(dipentafluorophenylphosphino)ethane, was prepared by the reaction of with excess amount of dfppe. When each of the starting complexes [PtCl(C^N)(dmso)], or , were reacted with 0.5 equiv. of any of the P^P ligands, the dimeric complexes [Pt2Cl2(ppy)2(µ-P^P)], , or [Pt2Cl2(bhq)2(µ-P^P)], , were formed. The complexes were fully characterized using multinuclear ((1)H and (31)P) NMR spectroscopy and elemental analysis. The structures of typical complexes , , , and were also confirmed by X-ray crystallography. The effect of ligands on the luminescent properties of the complexes was investigated and DFT calculations were performed to confirm the assignments.